Inselspital at Bern University Hospital uses Bayer’s radiological AI platform

Updated on:

Inselspital at Bern University Hospital uses Bayer's radiological AI platform

Source – Bayer

Bayer’s collection of digital X-ray, MRI, and CT imaging instruments powered by artificial intelligence will be used by a top teaching hospital in Switzerland.

One of the first to sign up for a subscription to Bayer’s cloud-hosted Calantic Digital Solutions platform in its radiology division is Inselspital at Bern University Hospital. It will also collaborate with the German team on real-world evidence (RWE) studies to demonstrate the advantages of using AI at scale in clinical settings.

With the use of Calantic’s technologies, radiologists may more efficiently identify and rank patients for treatment according to priority and detect and quantify disease lesions in medical pictures.

Additionally, it has a curated, vendor-neutral marketplace where radiologists may choose among applications that do additional activities including automating repetitive measures and chores, enhancing productivity in radiology suites, and freeing up time for other duties.

Additionally, according to Bayer, it will offer Inselspital Bern services for the platform’s installation and configuration, as well as staff training. Within a few months, it should be operational at the hospital’s Institute for Diagnostic and Interventional Neuroradiology.

When Calantic first launched last year, it offered apps for thoracic and neurological conditions such the identification of lung nodules, possible intracerebral hemorrhages (ICH), and large vascular occlusions (LVO), which may lead to stroke. Since then, applications for prostate and breast cancer have been introduced.

In order to expand the platform’s functionality, Bayer has worked with an increasing number of digital health businesses, including Avicenna, Icometrix, Nanox.AI, Riverain Technologies, and Vida.

“As AI is making its way into radiology, we are looking forward to joining forces with renowned experts such as Inselspital Bern to drive its adoption in clinical practice. Building on deep medical expertise across a multitude of diagnostic and therapeutic areas at Bayer, AI will continue to be a significant focus for us to help transform patient care.

Gerd Krueger, head of Bayer’s radiology division

Medical imaging is a key component of illness diagnosis, especially for cancer, but increasing demand and a scarcity of radiologists, which is made worse by burnout, are straining healthcare systems globally.

A 2018 research found that there are 40 million imaging-related errors worldwide each year, demonstrating that this pressure might result in diagnostic mistakes.

According to data from Signify Research, the market for AI in medical imaging was estimated by Bayer to be around $400 million in 2021 and be about $1.4 billion in 2026.

Share This News